EUR 2.66
(1.33%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 13.94 Million EUR | 84.71% |
2022 | 15.23 Million EUR | 54.36% |
2021 | 9.86 Million EUR | 9.73% |
2020 | 8.99 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 3.93 Million EUR | 0.0% |
2024 Q3 | - EUR | -100.0% |
2024 Q1 | - USD | -100.0% |
2023 Q4 | 3.18 Million EUR | -6.66% |
2023 FY | 13.94 Million EUR | -8.44% |
2023 Q3 | 3.41 Million EUR | -6.76% |
2023 Q2 | 3.65 Million EUR | -1.06% |
2023 Q1 | 3.69 Million EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | 15.23 Million EUR | 54.36% |
2021 FY | 9.86 Million EUR | 9.73% |
2020 FY | 8.99 Million EUR | 0.0% |
2019 FY | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Atrys Health, S.A. | 52.61 Million EUR | 73.49% |
Biotechnologies Assets SA | 3.45 Million EUR | -303.37% |
Pharma Mar, S.A. | 148.54 Million EUR | 90.61% |
Laboratorios Farmaceuticos Rovi, S.A. | 492.28 Million EUR | 97.167% |